OTLK
Outlook Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website outlooktherapeutics.com
- Employees(FY) 24
- ISIN US69012T3059
Performance
+0.65%
1W
-11.09%
1M
-13.86%
3M
-10.86%
6M
-1.27%
YTD
-67.58%
1Y
Profile
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Technical Analysis of OTLK 2024-05-10
Overview:
In analyzing the technical indicators for OTLK over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been consistently below the closing prices, ...
Recent News & Updates
- 2024-05-16 16:27
Q2 2024 Outlook Therapeutics Inc Earnings Call(Yahoo Finance)
- 2024-05-15 10:53
- 2024-05-15 05:00
- 2024-05-12 23:18
- 2024-05-12 20:50
- 2024-05-08 20:45
- 2024-05-01 21:05
- 2024-04-28 21:00
- 2024-04-25 18:37
- 2024-04-15 04:15
- 2024-04-15 00:54
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential(Yahoo Finance)
- 2024-04-10 03:30
Insiders are Piling into These 10 Healthcare Stocks in 2024(Insidermonkey)
- 2024-03-21 19:35
- 2024-03-18 05:10
- 2024-03-12 08:05
- 2024-03-11 20:05
- 2024-03-06 02:36
- 2024-02-25 00:37
- 2024-02-14 08:05
- 2024-02-14 04:27
- 2024-02-13 19:05
- 2024-01-31 08:05
Outlook Therapeutics® Doses First Subject in NORSE EIGHT(GlobeNewswire)
- 2024-01-30 19:05
Outlook Therapeutics Doses First Subject in NORSE EIGHT(Globenewswire)
- 2024-01-23 19:06
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study(Yahoo Finance)
- 2024-01-23 08:00
- 2024-01-22 19:00
- 2024-01-02 09:18
- 2023-12-27 01:03
- 2023-12-26 20:30
- 2023-12-26 01:15
Page 1 of 5
previousnext